<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Poirel, Laurent</dc:creator>
  <dc:creator>Ortiz de la Rosa, José Manuel</dc:creator>
  <dc:creator>Kieffer, Nicolas</dc:creator>
  <dc:creator>Dubois, Véronique</dc:creator>
  <dc:creator>Jayol, Aurélie</dc:creator>
  <dc:creator>Nordmann, Patrice</dc:creator>
  <dc:date>2019-01-01</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">A clinical Pseudomonas aeruginosa isolate resistant to all β-lactams, including  ceftolozane-tazobactam and carbapenems, was recovered. It belonged to sequence  type 235 and produced the extended-spectrum β-lactamase (ESBL) GES-6 differing  from GES-1 by two amino acid substitutions (E104K and G170S). GES-6 possessed  an increased hydrolytic activity toward carbapenems and to ceftolozane and a  decreased susceptibility to β-lactamase inhibitors compared to GES-1, except for  avibactam. We show here that resistance to ceftolozane-tazobactam may occur  through acquisition of a specific ESBL in P. aeruginosa but that ceftazidime-avibactam  combination remains an effective alternative.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/307569</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/307569/files/nor_aes.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1128/AAC.01809-18</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Antimicrobial Agents and Chemotherapy. - 2019, vol. 63, no. 1, p. e01809-18</dc:source>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Acquisition of extended-spectrum β-lactamase GES-6 leading to resistance to ceftolozane-tazobactam combination in Pseudomonas aeruginosa</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>